Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

Schedule of Product Warranty Liability [Table Text Block]

we also restated our December 31, 2013 Balance Sheet as it pertains to the Fair Value of our Warrants, Preferred Series C & D and Convertible Debentures to amounts as stated below from how they were originally reported as of December 31, 2013 in our Form 10-K:  

	December 31, 2013 (as previously reported)		Adjustments		December 31, 2013 (Restated)
Derivative Financial Instruments – warrants	$	684	$	(64)	$	620
Derivative Financial Instruments – Series C and D	$	23,606	$	(23,310)	$	296
Debentures payable – carried at fair value	$	257,451	$	(219,201)	$	38,250
Total Liabilities	$	284,576	$	(242,575)	$	42,001
Accumulated deficit	$	(479,485)	$	242,575	$	(236,910)
Total shareholders’ deficit	$	(284,435)	$	242,575	$	(41,860)

Schedule of Derivative Instruments [Table Text Block]

The table below reflects the changes in restating the derivative liabilities for the year ended December 31, 2013 (in thousands):

Derivative Liability Restatement for the 12 months ended December 31, 2013:

	Year Ended December 31, 2013 (as previously reported)		Adjustments		Year Ended December 31, 2013 (Restated)
Gain (loss) from change in fair value of hybrid financial instruments	$	(197,392)	$	219,201	$	21,809
Gain (loss) from change in fair value of derivative liability – warrants	$	3,003	$	64	$	3,067
Gain (loss) from change in fair value of derivative liability – Series C & D	$	(21,469)	$	23,310	$	1,841
Net income (loss)	$	(214,113)	$	242,575	$	28,462
Net income (loss) available to common shareholders	$	(214,855)	$	242,575	$	27,720
Comprehensive income (loss)	$	(213,980)	$	242,575	$	28,595

Schedule Of Derivative Instruments In Statement Of Cash Flows Fair Value [Table Text Block]

Statement of Cash Flow:

	Year Ended December 31, 2013 (as previously reported)		Adjustments		Year Ended December 31, 2013 (Restated)
Net income (loss)	$	(214,113)	$	242,575	$	28,462
Gain (loss) from change in fair value of hybrid financial instruments	$	(197,392)	$	219,201	$	21,809
Gain (loss) from change in fair value of derivative liability – warrants	$	3,003	$	64	$	3,067
Gain (loss) from change in fair value of derivative liability – Series C & D	$	(21,469)	$	23,310	$	1,841
Net cash used in operating activities	$	(399)	$	-	$	(399)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

The following table reflects the outstanding stock options, warrants, convertible debt and convertible preferred securities as of December 31, 2013 and 2012, which have been excluded from the diluted loss per common share calculation because inclusion of the securities would be anti-dilutive:

	December 31,
	2013	2012
Stock options	1,173,020	1,340,000
Warrants	499,990,063	1,882,492,690
Convertible debt	234,287,861,850	22,696,138,542
Convertible preferred stock	26,617,345,361	990,409,508
	261,406,370,294	25,570,380,740

Schedule of Finite-Lived Intangible Assets [Table Text Block]

Intangible assets are amortized, using the straight-line method, over the estimated period of benefit as noted below:

Capitalized patents	5 - 17 years
Customer contracts	5 years
Copyrighted materials	5 years
Acquired software products	7 years
Brand names	10 years

Schedule Of Property Plant and Equipment Estimated Useful Lives [Table Text Block]

Depreciation is recorded on a straight-line basis over the estimated useful lives of the assets as noted below:

Furniture and fixtures	3 - 7 years
Equipment	2 - 5 years